By integrating design, rapid manufacturing, and analytics, we help partners de-risk RNA drug development programs.
Contact us
Rapid RNA prototyping for eCOMPASS
To accelerate iterative RNA design, we provide rapid, small-scale RNA prototyping to support lab-in-the-loop optimization through our eCOMPASS platform. Once a lead candidate is selected, we help teams transition efficiently by identifying trusted partners for scale-up and GMP manufacturing.
Contact usOverview
Use:
Lab-in-the-loop RNA prototyping
Typical samples:
Linear mRNA
Close the loop with RNA prototyping
Our rapid production capabilities shorten timelines for iterative design, while our network of validated manufacturing partners ensures seamless transition to scale when needed.
Prototype with confidence
We have optimized our in-house capabilities to produce challenging RNA constructs, including linear mRNAs greater than 10 kb. This enables rapid iteration across designs until the optimal candidate is identified.
Example fragment analyzer trace from an in-house RNA construct, demonstrating high yield and integrity suitable for iterative design and validation.
Prepare for scale
One of the biggest challenges after identifying a lead candidate is selecting the right partner for scale-up and GMP manufacturing. Through our network of validated manufacturing partners, we help pair you with the optimal vendor to produce your therapy for the clinic.
All members of our manufacturing network undergo rigorous evaluation using eMERGE analytics to ensure consistency and quality. Shown here is an example of poly(A) tail length distributions from two manufacturers, highlighting differences in production consistency.
Manufacture for clinical success
Our in-house manufacturing is a pillar of our eCOMPASS platform that combines design, manufacturing, and characterization to generate mRNA candidates that meet your regulatory needs.
eCOMPASS integrates eNAVIGATE's AI-driven design, in-house prototyping, and eMERGE's sequencing-based characterization in a single platform to produce de-risked mRNA candidates ready for IND-enabling studies.